Zepbound sales keep soaring, even as weight loss drug growth slows
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter, despite missing the company’s initial sales expectations.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments
Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in
Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss
Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
Lilly forecasts 2025 profit largely above estimates on weight-loss drug strength
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular diabetes and weight-loss treatments in new markets. The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter.
Lilly's profit forecast bring investors some relief amid Zepbound miss
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...
BioSpace6h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...
FiercePharma6h
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...
Zacks.com on MSN7h
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates
Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
FierceBiotech4h
Eli Lilly’s next R&D focus: Testing incretin meds in neuro, immunology fields
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly reports mixed earnings, increases 2025 guidance
Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...
Why Eli Lilly Stock Popped on Thursday
Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...
Hosted on MSN5h
Lilly's profit doubles in fourth quarter, driven by Mounjaro and Zepbound sales
Lilly's profit doubled in the fourth quarter, driven by its diabetes and obesity treatments Mounjaro and Zepbound, while ...